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A B S T R A C T
Secondary acute myeloid leukemia (sAML) has been associated with inferior outcomes compared with de novo
AML. Little is known about patient risk factors and outcomes in sAML after allogeneic hematopoietic stem cell
transplantation (HCT); thus, this large systemic analysis of the European Society for Blood and Bone Marrow
Transplantation registry was performed. This study included 4997 patients with sAML who received HCT from
2000 to 2016. In univariate analysis the 2-year cumulative incidence of chronic graft-versus-host disease (GVHD),
relapse, and nonrelapse mortality (NRM) were 33.5% (95% conﬁdence interval [CI], 32% to 34.9%), 33.7% (95%
CI, 32.3% to 35.1%), and 27.5% (95% CI, 26.1% to 28.7%), respectively. Overall survival (OS), leukemia-free surviv-
al (LFS), and GVHD-free, relapse-free survival (GRFS) at 2 years were 44.5% (95% CI, 43% to 46%), 38.8% (95% CI,
37.4% to 40.3%), and 27.2% (95% CI, 25.9% to 28.6%), respectively. In multivariate analysis, patients receiving
myeloablative regimens had decreased relapse (hazard ratio, .859; 95% CI, .761 to .97; P = .01), higher NRM (hazard
ratio, 1.175; 95% CI, 1.03 to 1.341; P = .02), and no differences in OS, LFS, and GRFS comparedwith patients receiving
reduced-intensity conditioning regimens. Active disease, adverse cytogenetics, older age, Karnofsky perfor-
mance status (≤80%), ex vivo T cell depletion, other malignant hematologic diseases, and patient cytomegalovirus
seropositivity were associated with inferior OS and LFS. These variables should be considered in patients with
sAML in need of HCT, and further study regarding the impact of conditioning regimens on relapse is needed.
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Acute myeloid leukemia (AML) is a heterogeneous disease
that remains challenging to treat, regardless of whether it
occurs de novo or secondary to an antecedent malignancy
or its treatment. Hematopoietic stem cell transplantation
(HCT) is the postremission treatment of choice in high-risk
AML patients. It is unclear what percentage of all cases of AML
are due to secondary AML (sAML) because of poor report-
ing, undiagnosed antecedent myelodysplastic syndrome
(MDS), and exclusion from most clinical trials. However, it
is believed that sAML comprises a signiﬁcant proportion of
all cases of AML and constitutes a high-risk subtype [1-3].
The World Health Organization has historically deﬁned
sAML as AML that occurs with an antecedent myeloid disease
such as MDS or a myeloproliferative neoplasm (MPN) re-
gardless of prior therapy. Therapy-related AML is deﬁned as
AML that has occurred as a complication of prior cytotoxic
chemotherapy or radiation therapy for either a solid tumor
or hematologic malignancy [4]. Studies in the past have com-
bined these 2 categories as sAML [3,5-7], and both categories
have been shown to have inferior outcomes compared with
de novo AML [1,8-10]. Data have shown that this is in part
due to the higher frequency of adverse molecular muta-
tions and high-risk cytogenetic abnormalities such as TP53
in patients with sAML, particularly in patients with therapy-
related AML [11-14]. Furthermore, these patients also tend
to be of older age at diagnosis, have hadmore preceding treat-
ment, and also are more likely to have a poor response to
standard intensive chemotherapy. However, it remains unclear
if it is sAML itself that is an independent poor prognostic factor
despite the aforementioned variables [8,9,15-17].
Some population-based studies have shown that pa-
tients with an antecedent hematologic disease, particularly
that of non-MDS AML, tend to have poorer outcomes, par-
ticularly younger patients. Ostgardt et al. [18] reported in their
national population-based study that patients with an an-
tecedent myeloid disorder or prior cytotoxic exposure had
decreased complete remission (CR) rates and poorer overall
survival (OS) after intensive therapy. Increased age and adverse
cytogenetics were also critical determinants of outcomes,
except in patients who had non-MDS AML, in which out-
comes were dismal despite taking into account age and
cytogenetics [1,18].
Although these prognostic factors are known in patients
with sAML who undergo initial chemotherapy, what remains
unclear is how these variables affect outcomes as they relate
to patients who ultimately undergo HCT—likely the only po-
tentially curative treatment for this disease. Risk factors and
outcomes based on the antecedent disease and other
pretransplant factors after allogenic HCT are largely unknown.
Therefore, the Acute Leukemia Working Party (ALWP) of the
European Society for Blood and Bone Marrow Transplanta-
tion (EBMT) performed the largest registry study to date on
patients with sAML undergoing HCT to study this further.
METHODS
Study Design and Data Collection
We used the EBMT registry to identify 4997 patients with a diagnosis
of sAMLwho received HCT between 2000 and 2016 in this retrospective mul-
ticenter analysis. Data were provided by the ALWP of the EBMT group registry.
The EBMT registry is a voluntary working group of more than 500 trans-
plant centers that are required to report all consecutive stem cell
transplantations and follow-ups once a year. The audits are routinely per-
formed to determine the accuracy of the data. Since 1990, patients have
provided informed consent authorizing the use of their personal informa-
tion for research purposes. The study was approved by the general assembly
of ALWP.
Eligibility criteria for this analysis included adult patients (ages > 18 years)
with a diagnosis of sAML. Patients with sAML were deﬁned as patients di-
agnosed with AML who had an antecedent MDS, MPN, overlap MDS/MPN,
other malignant hematologic disorder (OMHD), bone marrow failure syn-
drome, or solid tumorwith prior chemotherapy or radiation therapy. Variables
collected included recipient and donor characteristics (age, gender, cyto-
megalovirus [CMV] serostatus), disease features, previous diagnosis (MDS/
MPN, OMHD, bone marrow failure syndrome, solid tumor), cytogenetics
(favorable, intermediate, adverse), Karnofsky performance status (KPS) at
transplant, disease status at transplant (ﬁrst CR [CR1] versus CR2/3 versus
active disease [≥5% blasts in bone marrow]), transplant-related factors in-
cluding conditioning regimen (myeloablative conditioning [MAC] or reduced-
intensity conditioning [RIC]), donor type (matched sibling donor, unrelated
donor, other relative [haploidentical], or cord blood transplant [CBT]), degree
of match (10/10, 9/10, or haploidentical), immunosuppression (in vivo T cell
depletion [TCD] versus none), graft-versus-host-disease (GVHD) prophy-
laxis, and outcome variables (acute and chronic GVHD [aGVHD, cGVHD],
relapse, nonrelapse mortality [NRM], leukemia-free survival [LFS], OS, and
causes of death).
Statistical Analysis
The primary endpoint of the study was OS and LFS. Secondary end-
points included disease relapse incidence, NRM, engraftment, incidences and
severity of aGVHD and cGVHD, and GVHD-free, relapse-free survival (GRFS).
The starting point for time-to-event analysis was date of transplantation.
OS was deﬁned as the time to death from any cause. LFS was deﬁned as sur-
vival without relapse or progression. Patients surviving were censored at
time of last follow-up. Relapse incidence was deﬁned as time to onset of
leukemic recurrence. NRM, deﬁned as death without relapse or progres-
sion, was the competing risk, and patients surviving in continuous CR were
censored at last contact.
Cumulative incidence curves were used for relapse incidence and NRM
in a competing risk setting, because death and relapse are competing. Prob-
abilities of OS, LFS, and GRFSwere calculated using the Kaplan-Meier method.
Cumulative incidence was used to estimate the endpoints of NRM, relapse
incidence, aGVHD, and cGVHD to accommodate competing risks. To study
aGVHD and cGVHD, we considered relapse and death to be competing events.
Univariate analyses were done using the Gray’s test for cumulative inci-
dence functions and the log rank test for OS, GRFS, and LFS. A Cox proportional
hazards model was used for multivariate regression on all patients except
AML secondary to bone marrow failure syndrome because of a low number
of patients. All variables associated with one outcome in univariate analy-
sis were included in the Cox model.
Results were expressed as the hazard ratio (HR) with the 95% conﬁ-
dence interval (95% CI). Proportional hazards assumptions were checked
systematically for all proposedmodels using the Grambsch-Therneau residual-
based test. All tests were 2-sided. The Type I error rate was ﬁxed at .05 for
the determination of factors associated with time-to-event outcomes. Sta-
tistical analyses were performed with SPSS 24.0 (SPSS Inc, Chicago, IL) and
R 3.4.1 (R Foundation for Statistical Computing, Vienna, Austria [https://
www.R-project.org/]).
RESULTS
Patient, Disease, and Transplant Characteristics
Details of patient, disease, and transplant characteristics
are summarized in Tables 1 and 2. Included in this study were
4997 patients with sAML who underwent HCT between 2000
and 2016. Most patients had a prior diagnosis of MDS/MPN
(3960, including 663 MPN), OMHD (467, including 73 pa-
tients with acute leukemia, 56 with chronic leukemia, 318
with lymphomas, and 20 with plasma cell disorders), solid
tumor (537, including 324 patients with breast cancer), or
bone marrow failure syndrome, predominantly severe aplas-
tic anemia (33). Median age at time of HCT was 58 years
(interquartile range, 50 to 64). Median time from diagnosis
to HCT was 4.62 months (interquartile range, 3.18 to 6.89).
Median follow-up of surviving patients was 27 months
(interquartile range, 7.35 to 60.63).
At the time of transplantation, 2625 patients (52.5%) were
in CR1, 290 (8.2%) were in CR2 or beyond, and 2082 pa-
tients (41.7%) had active disease. Medical Research Council
cytogenetic classiﬁcation data at the time of diagnosis of sAML
were available in 2016 patients (40%; favorable, 74; inter-
mediate, 1255; adverse, 687). One thousand nine hundred
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seventy-six patients (39.7%) receivedMAC regimens and 3005
patients (60.3%) RIC regimens (missing = 16). The most com-
monly used MAC regimens included total body irradiation
(n = 528), busulfan-cyclophosphamide (n = 452), and busulfan-
ﬂudarabine (n = 383), whereas the most common RIC
regimens were busulfan-ﬂudarabine (n = 899), ﬂudarabine-
melphalan (n = 619), and total body irradiation (n = 563).
Donor sources were matched sibling donor in 1532 pa-
tients (41.7%), unrelated donor (9/10 or 10/10) in 2957 patients
(59.2%), other relative (haploidentical) in 320 patients (6.4%),
and CB in 173 (3.5%). Female donor for male recipients were
used in 875 cases (17.7%), and 1097 patient–donor pairs
(24.4%) were CMV negative pre-HCT.
All patients received calcineurin inhibitor–based GVHD
prophylaxis, and 2988 (63.9%) received in vivo TCD (most
rabbit antithymocyte globulin). Most patients had a KPS of
80% or greater (4165, 91.5%) at the time of transplant. CMV
status is outlined in Table 1. Myeloid engraftment occurred
in most patients who underwent HCT (4176, 94.5%); 244
(5.5%) had graft failure with no difference in incidence based
on disease type (MDS/MPN versus solid tumor versus OMHD;
P = .2) or donor type with the exception of patients who re-
ceived CBT (P < .0001). Grades II to IV aGVHD by day 100 was
seen in 1317 patients (28%; 95% CI, 26.8% to 29.3%), whereas
cumulative incidence of grades III to IV aGVHD by day 100
was 11.8% of patients (95% CI, 10.9% to 12.8%).
Toxicity and NRM
Overall transplant outcomes are shown in Table 3. The
2-year cumulative incidence of NRMwas 27.4% (95% CI, 26.1%
to 28.7%) (Figure 1, Table 4). The major causes of NRM were
infection and GVHD, which occurred in 615 (24.4%) and 414
(15.5%) of patients, respectively. Death from organ toxicity
such as cardiac toxicity, veno-occlusive disease, and bleed-
ing complications was very low, at approximately 1% each.
Other causes of death are outlined in Table 4. In multivari-
able analysis, factors associated with higher NRM included
patients transplanted with active disease (HR, 1.58; 95% CI,
1.38 to 1.79); patients with OMHD (HR, 1.31; 95% CI, 1.05 to
1.63) compared with prior diagnosis of MDS/MPN; older age
(HR per 10 years, 1.20; 95% CI, 1.12 to 1.27); adverse cyto-
genetics (HR, 1.87; 95% CI, 1.00 to 3.46); patients who received
MAC (HR, 1.17; 95% CI, 1.03 to 1.34); patients transplanted
from unrelated donor (HR, 1.44; 95% CI, 1.22 to 1.69), other
relative (HR, 1.68; 95% CI, 1.31 to 2.17), or CBT (HR, 1.94; 95%
CI, 1.37 to 2.75) comparedwithmatched sibling donor; patient
CMV seropositivity (HR, 1.25; 95% CI, 1.09 to 1.43); and those
who received ex vivo TCD (HR, 1.66; 95% CI, 1.2 to 2.28).
Female gender and good KPS > 80% were associated with a
lower NRM (HR, .84; 95% CI, .74 to .96; and HR, .59; 95% CI,
.60 to .78, respectively). Factors that did not appear to impact
NRM were donor gender and donor CMV seropositivity
(Table 6).
Relapse
The 2-year cumulative incidence of relapse was 33.7%
(95% CI, 32.3 to 35.1) (Figure 1, Table 5). In multivariate
analysis the incidence of relapse was signiﬁcantly higher in
patients who were transplanted with active disease (HR,
1.67; 95% CI, 1.48 to 1.87), had adverse cytogenetics (HR,
2.41; 95% CI, 1.44 to 4.04), and underwent ex vivo TCD
(HR, 1.45; 95% CI, 1.07 to 1.98). Patients who had good KPS
> 80% (HR, .79; 95% CI, .65 to .95), received MAC and who
underwent transplantation from an unrelated donor had
decreased risk of relapse post-HCT. There was no difference
in relapse risk among patients with prior MDS/MPN, OMHD,
or solid tumors (Table 6).
Table 1
Patient, Disease, and Transplant Characteristics
Characteristic Value Percentage













































































































Missing data: donor age, 2179; cytogenetics NA/failed, 2981 (59.6%); KPS,
444; conditioning regimen, 16; GVHD prophylaxis, 334; patient CMV se-
rology, 405; donor CMV serology, 444; aGVHD, 240; engraftment, 577. IQR
indicates interquartile range; BMFS, bone marrow failure syndrome; CSA,
cyclosporine; MTX, methotrexate; MMF, mycophenolate mofetil; Tacro,
tacrolimus; Siro, sirolimus; PTCY, post-transplant cyclophosphamide.
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LFS and OS
The 2-year cumulative incidence of LFS in this cohort
was 38.8% (95% CI, 37.4% to 40.3%) (Figure 1, Table 4). In
multivariable analysis, LFS was signiﬁcantly lower for pa-
tients who were transplanted with active disease (HR, 1.63;
95% CI, 1.49 to 1.77), those with older age (HR, 1.08; 95% CI,
1.04 to 1.13), adverse cytogenetics (HR, 2.15; 95% CI, 1.45 to
3.20), those who underwent ex vivo TCD (HR, 1.54; 95% CI,
1.23 to 1.92), and those with OMHD (HR, 1.17; 95% CI, 1.01
to 1.35). Results of multivariate analysis of LFS are summa-
rized in Table 6. As expected, patients with better KPS had
better LFS.
The OS of the entire cohort at 2 years was 44.5% (95% CI,
43% to 46%) (Figure 1, Table 4). Multivariable analysis showed
lower OS for patients who were transplanted in CR2 or with
active disease (HR, 1.23; 95% CI, 1.02 to 1.49; and HR, 1.61;
95%, CI 1.47 to 1.76, respectively). In terms of disease types,
patients who had OMHD also had poorer OS (HR, 1.20; 95%
CI, 1.03 to 1.39). As expected, patients with adverse cytoge-
netics had also signiﬁcantly worse OS (HR, 2.28; 95% CI, 1.49
to 3.50). Other transplant-related factors with inferior sur-
vival outcomes included older patients, those patients who
underwent transplant with a CBT or a haploidentical donor,
patients with CMV seropositivity, and those who under-
went ex vivo TCD. There was no difference in LFS or OS in
patients who received RIC regimens comparedwith thosewho
received MAC regimens. Results of multivariable analysis of
OS are summarized in Table 6.
In summary, active disease, adverse cytogenetics, older age,
KPS (≤80%), ex vivo TCD, OMHD and patient CMV seroposi-
tivity were the variables associated with inferior OS and LFS.
Receipt of a haploidentical transplant or CBT was associ-
ated with lower OS but was not signiﬁcant for LFS (Table 6).
Graft-versus-Host Disease
The 2-year cumulative incidence of cGVHDwas 33.5% (95%
CI, 13.9% to 16.1%), with incidence of extensive cGVHD at 15%
(95% CI, 13.9% to 16.1%). Univariate analysis of GVHD is sum-
marized in Table 7. Two-year GRFS was 27.2% (95% CI, 25.9%
to 28.6%).
In multivariable analysis, factors that were associated with
signiﬁcantly increased risk of grades II to IV aGVHD were
active disease at transplant (HR, 1.31; 95% CI, 1.15 to 1.49),
use of an unrelated donor (HR, 1.47; 95% CI, 1.26 to 1.72) or
CBT (HR, 1.49; 95% CI, 1.03 to 2.16), and use of MAC regi-
mens (HR, 1.23; 95% CI, 1.08 to 1.41) (Table 8). Women and
patients who underwent in vivo TCD had lower risk of grades
II to IV aGVHD (HR, .86; 95% CI, .76 to .98; and HR, .71; 95%
CI, .62 to .82, respectively). In terms of risk of cGVHD, active
disease (HR, 1.19; 95% CI, 1.05 to 1.36) and donor female versus
male were the only 2 variables with statistically signiﬁcant
Table 2













Median age at treatment 59 59.8 49.4 53.8 53.5 45.5
Range (18.1-79.3) (22.1-75.4) (18.3-75.9) (18.4-71.8) (18.8-76) (21-65.6)
IQR (51.2-64.5) (53.9-65.2) (38.8-59.5) (39.6-61) (46.2-60.6) (36.4-53.7)
Median year of treatment 2011 2012 2010.5 2011 2010 2009
Range (2000-2016) (2000-2016) (2000-2016) (2000-2016) (2000-2016) (2001-2015)
Median time of previous
diagnosis to treatment, mo
7 12 60.5 60.8 43 105
Range (1-390.5) (1-438.1) (1-498.1) (1-438.6) (1-475.6) (4.4-318.6)
IQR (2.8-16.1) (4.4-33.8) (29.8-111.7) (32.9-100.5) (24.9-76.8) (59.9-158.7)
Sex
Male 2002 (60.78%) 434 (65.46%) 179 (56.29%) 100 (67.11%) 109 (20.3%) 21 (63.64%)
Female 1292 (39.22%) 229 (34.54%) 139 (43.71%) 49 (32.89%) 428 (79.7%) 12 (36.36%)
Missing 3 0 0 0 0 0
Cytogenetics
Favorable 9 (.94%) 0 (0%) 15 (7.32%) 3 (2.91%) 47 (10.28%) 0 (0%)
Intermediate 623 (65.24%) 197 (72.43%) 102 (49.76%) 62 (60.19%) 259 (56.67%) 12 (50%)
Adverse 323 (33.82%) 75 (27.57%) 88 (42.93%) 38 (36.89%) 151 (33.04%) 12 (50%)
NA/Failed 2342 391 113 46 80 9
Donor type
Matched sibling 971 (29.45%) 193 (29.11%) 122 (38.36%) 39 (26.17%) 212 (39.48%) 10 (30.3%)
Unrelated 2020 (61.27%) 410 (61.84%) 164 (51.57%) 86 (57.72%) 259 (48.23%) 18 (54.55%)
Haploidentical 204 (6.19%) 46 (6.94%) 20 (6.29%) 15 (10.07%) 33 (6.15%) 2 (6.06%)
CBT 102 (3.09%) 14 (2.11%) 12 (3.77%) 9 (6.04%) 33 (6.15%) 3 (9.09%)
Table 3
Overall Transplant Outcomes
Outcome Percentage 95% CI
2-Year LFS 38.8 37.4-40.3
2-Year OS 44.5 43-46
2-Year relapse incidence 33.7 32.3-35.1
2-Year NRM 27.4 26.1-28.7
aGVHD grades II-IV (100 day) 28 26.8-29.3
aGVHD grades III-IV (100 day) 11.8 10.9-12.8
2-Year chronic GVHD 33.5 32-34.9
2-Year extensive chronic GVHD 15 13.9-16.1
2-Year GRFS 27.2 25.9-28.6
Table 4
Causes of Death




Other treatment related 153 5.7
Interstitial pneumonitis 49 1.8
Veno-occlusive Disease 45 1.7
Second malignancy 43 1.6
Hemorrhage 31 1.2
Cardiac toxicity 29 1.1
Failure/rejection 11 .4
Missing: n = 197.
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adverse impact in this cohort. Patients who underwent CBT
and in vivo TCD were noted to have a lower risk of cGVHD
(HR, .43; 95% CI, .27 to .69; and HR, .63; 95% CI, .55 to .73,
respectively) (Table 7). For GRFS in multivariate analysis, pa-
tients who were transplanted beyond CR1 had poorer
outcomes (CR2: HR, 1.22; 95% CI, 1.03 to 1.44; CR3: HR, 1.55;
95% CI, 1.43 to 1.68), whereas adverse cytogenetics, older age,
poorer KPS, and female donor were all also associated with
inferior GRFS. History of in vivo TCD was associated with a
higher GRFS. Multivariable analysis of GVHD-related out-
comes are summarized in Table 8.
DISCUSSION
AML remains a therapeutic challenge, particularly in pa-
tients with sAML. Consensus remains that allogeneic
transplantation remains the best treatment option for pa-
tients with high-risk AML after intensive therapy, although
speciﬁc outcomes for patients with sAML with HCT remain
largely unknown. What is known in the literature is that pa-
tients with sAML, if treated conservatively, have a poorer
prognosis than patients with de novo AML [8,19-23]. This
present study is a large registry study retrospectively evalu-
ating allogeneic transplantation outcomes in 4997 patients
with sAML, including patients with an antecedent hemato-
logic malignancy or patients with treatment-related disease,
within the EBMT registry. To our knowledge, this is the largest
registry study in patients with sAML undergoing transplan-
tation to date.
OS, LFS, and GRFS at 2 years were 44.5% (95% CI, 43% to
46%), 38.8% (95% CI, 37.4% to 40.3%), and 27.2% (95% CI, 25.9%
to 28.6%), respectively, which is in line with reported data on
survival outcomes for patients after allogeneic transplanta-
tion for AML [24]. However, multivariate analysis showed that
those patients in our cohort who underwent MAC had lower
incidences of relapses, but this was at the cost of higher NRM
with no associated differences in survival outcomes.
Figure 1. Transplant outcomes based on disease type before developing sAML.
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Although speciﬁc disease types had no effect on relapse in-
cidence, having a prior hematologic malignancy other than
an MDS/MPN was independently shown to affect NRM and
poorer survival. As expected, certain patient variables such
as having active disease before transplant, adverse cytoge-
netics, older age, poor KPS, and CMV seropositivity were
associated with poorer survival outcomes as well. Patients
who needed alternative donor transplants such as from CB
or a haploidentical donor also had inferior outcomes in this
study, although the numbers of those transplants were low.
Relapse after allogeneic transplantation for treatment of
AML remains a challenge, accounting for approximately 40%
of cases of treatment failure, and is the major cause of treat-
ment failure after transplant [25]. Survival after post-
transplant relapse is dismal, with less than 20% survival at
2 years postrelapse. Our study showed a cumulative inci-
Table 5
Univariate Analysis of Relapse, NRM, LFS, OS, and GRFS at 2 Years
2 Years
Relapse NRM LFS OS GRFS
Diagnosis MDS 32.1% [30.4-33.8] 28% [26.4-29.6] 40% [38.1-41.8] 45.6% [43.8-47.5] 28.3% [26.6-30]
MPN 41.4% [37.4-45.4] 28.4% [24.8-32.1] 30.2% [26.3-34] 36.9% [32.7-41] 18.9% [15.5-22.2]
Lymphoma 36.7% [31.2-42.3] 31.6% [26.3-37] 31.5% [26-37] 38.1% [32.3-43.9] 22.4% [17.4-27.4]
OMHD 32.6% [24.8-40.5] 24.7% [17.9-32.2] 42.7% [34.3-51.1] 45.7% [37.1-54.2] 32.2% [24.2-40.3]
Solid tumor 34.1% [30-38.3] 21.6% [18.1-25.3] 44.2% [39.8-48.6] 49.1% [44.7-53.6] 31% [26.8-35.1]
BMFS 18.2% [7.2-33.1] 30.3% [15.6-46.4] 51.5% [34.5-68.6] 53% [35.5-70.4] 37.5% [20.7-54.3]
P value .14787 .011271 .002938 .0050347 .0087063
If MDS or MPN MDS (n = 3258) 31.9% [30.2-33.6] 28% [26.4-29.6] 40.1% [38.3-41.9] 45.7% [43.9-47.6] 28.4% [26.7-30.1]
MPN n = (663) 41.4% [37.4-45.4] 28.4% [24.8-32.1] 30.2% [26.3-34] 36.9% [32.7-41] 18.9% [15.5-22.2]
P value 2.6285e-06 .95726 1.5865e-06 3.598e-05 3.9211e-06
If solid tumor Other solid tumor (n = 213) 32.7% [26.3-39.3] 22.1% [16.6-28.1] 45% [38-52] 49.4% [42.3-56.5] 33.3% [26.5-40]
Breast cancer (n = 324) 35% [29.7-40.4] 21.2% [16.8-26] 43.7% [38-49.3] 49% [43.3-54.7] 29.5% [24.2-34.7]
P value .51523 .69031 .71704 .78656 .49289
Status at transplant CR1 30.4% [28.5-32.3] 23.2% [21.4-24.9] 46.4% [44.4-48.5] 52.3% [50.2-54.4] 33.8% [31.8-35.8]
CR2/3 33.2% [27.4-39.1] 26% [20.8-31.6] 40.5% [34.3-46.7] 47.4% [41.1-53.7] 27.9% [22.3-33.5]
Active disease 37.8% [35.7-40] 33% [30.9-35.1] 29.2% [27.1-31.3] 34.5% [32.3-36.7] 19.1% [17.3-20.9]
P value 4.3669e-07 1.3878e-14 1.2997e-46 1.0328e-43 1.1814e-41
Donor Type MSD 39.3% [36.7-41.8] 20.2% [18.1-22.3] 40.5% [37.9-43.1] 46.6% [43.9-49.3] 26.1% [23.7-28.4]
UD 10/10 29.2% [26.6-31.8] 27.3% [24.8-29.8] 43.5% [40.6-46.4] 49% [46.1-51.9] 31.8% [29.1-34.6]
UD 9/10 30.2% [25.5-35] 35.7% [30.8-40.7] 34.1% [29.1-39] 39.4% [34.3-44.6] 24.7% [20.1-29.3]
Haploidentical 31.8% [26.4-37.5] 36% [30.5-41.6] 32.1% [26.5-37.8] 36.8% [30.9-42.7] 24.5% [19.3-29.7]
CBT 30.1% [23.3-37.3] 37.3% [29.9-44.6] 32.6% [25.4-39.8] 35.8% [28.4-43.2] 24.2% [17.6-30.9]
P value 6.5137e-09 5.5067e-14 .0071672 1.7164e-05 .076925
Values are HRs with 95% CIs in brackets. MSD indicates matched sibling donor; UD, unrelated donor.
Table 6
Multivariate Analysis of Relapse, NRM, LFS, and OS
Relapse NRM LFS OS
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
CR1 (reference)
CR2/3 1.104 .83-1.469 .49563 1.157 .852-1.571 .34939 1.134 .921-1.397 .23493 1.191 .961-1.478 .11109
Active disease 1.728 1.516-1.97 <10-5 1.429 1.228-1.663 <10-5 1.595 1.445-1.761 <10-5 1.544 1.392-1.712 <10-5
MDS (reference)
MPN 1.499 1.266-1.774 <10-5 1.024 .83-1.263 .82416 1.28 1.123-1.46 .00022 1.234 1.075-1.417 .0029
Lymphoma 1.2 .924-1.559 .17244 1.557 1.175-2.064 .00206 1.353 1.117-1.639 .00198 1.328 1.087-1.624 .00561
OMHD 1.079 .733-1.587 .70126 1.043 .683-1.594 .84501 1.056 .794-1.405 .70935 1.071 .796-1.441 .6521
Solid tumor 1.165 .938-1.447 .16679 .921 .7-1.211 .55502 1.069 .903-1.267 .43708 1.067 .894-1.273 .47357
BMFS .441 .164-1.185 .10434 .428 .137-1.342 .14563 .441 .209-.931 .03164 .488 .231-1.031 .05998
Age (per 10 yr) 1.017 .958-1.08 .57554 1.238 1.148-1.334 <10-5 1.103 1.053-1.156 4e-05 1.125 1.071-1.182 <10-5
Good risk cytogenetics
(reference)
Intermediate risk 1.193 .7-2.034 .51656 1.68 .851-3.315 .13488 1.362 .896-2.069 .14834 1.386 .887-2.167 .15213
Adverse risk 2.309 1.35-3.949 .00225 2.102 1.055-4.184 .03455 2.202 1.443-3.359 .00025 2.249 1.433-3.527 .00042
NA/failed 1.454 .851-2.486 .1708 1.723 .87-3.41 .11858 1.549 1.017-2.359 .0414 1.626 1.039-2.547 .0335
KPS > 80% .854 .689-1.059 .15006 .546 .441-.677 <10-5 .691 .594-.804 <10-5 .646 .552-.755 <10-5
MSD (reference)
UD 10/10 .667 .573-.777 <10-5 1.295 1.076-1.559 .00622 .874 .778-.982 .02386 .981 .867-1.109 .75359
UD 9/10 .759 .612-.941 .01172 1.714 1.357-2.166 1e-05 1.07 .915-1.251 .39699 1.239 1.052-1.458 .01015
Haploidentical .84 .641-1.099 .20333 1.622 1.228-2.144 .00067 1.11 .916-1.344 .28829 1.274 1.046-1.552 .01612
CBT .811 .565-1.165 .25634 1.94 1.37-2.745 .00019 1.182 .922-1.516 .18699 1.292 1-1.669 .04961
Patient female vs. male 1.069 .939-1.216 .31324 .813 .699-.947 .00759 .949 .86-1.047 .29463 .917 .827-1.016 .09847
Donor female vs. male .881 .773-1.003 .05582 1.091 .939-1.266 .25572 .963 .873-1.062 .45069 1.002 .904-1.11 .96839
MAC vs. RIC .85 .74-.976 .02114 1.219 1.045-1.422 .01154 .993 .896-1.101 .89856 1.009 .906-1.124 .87287
Patient CMV positive 1 .871-1.148 .99682 1.217 1.035-1.432 .01779 1.09 .981-1.21 .10961 1.117 1-1.249 .0496
Donor CMV positive 1.023 .896-1.167 .74104 .952 .819-1.105 .51514 .989 .896-1.092 .8302 1.016 .916-1.127 .76436
In vivo TCD 1.109 .963-1.277 .15175 .984 .837-1.156 .84434 1.054 .948-1.173 .32863 .986 .882-1.102 .80596
Ex vivo TCD 1.384 .947-2.022 .09329 1.93 1.337-2.787 .00045 1.612 1.239-2.098 .00038 1.634 1.249-2.136 .00034
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dence of relapse to be similar to previous studies and similarly
was themajor cause of treatment failure in our cohort [26-30].
Patients who receivedMAC as part of their treatment did have
a signiﬁcantly decreased risk of relapse, although no impact
on survival was seen. Our study suggests that for patients who
are deemed particularly high risk for relapse, it may be rea-
sonable to consider MAC for suitable patients, although
additional studies are needed to conﬁrm this. Additionally,
sAML patients with 1 or more variables that were associ-
ated with inferior survival outcomes such as active disease,
adverse risk cytogenetics, and older age should be edu-
cated on these risks associatedwith sAML and transplantation.
It may be that patients who harbor these higher risk factors
should be considered for less intensive therapy other than
HCT.
Some limitations of this study include its retrospective
nature and its inherent drawbacks. Additionally, the catego-
rization of MDS/MPN into 1 disease entity may perhaps be
Table 7
Univariate Analysis of GVHD
100 Days 2 Years
aGVHD Grades II-IV aGVHD Grades III-IV cGVHD Extensive cGVHD
Diagnosis MDS 27.6% [26-29.2] 12.1% [11-13.3] 34.8% [33-36.6] 15% [13.7-16.4]
MPN 28.1% [24.6-31.7] 11.2% [8.8-13.8] 32.3% [28.3-36.4] 15.7% [12.7-19]
Lymphoma 33.8% [28.5-39.2] 14.6% [10.9-18.9] 27.8% [22.6-33.3] 13.1% [9.3-17.4]
OMHD 24.4% [17.6-31.8] 9.4% [5.3-15] 28.4% [20.8-36.4] 15% [9.4-21.9]
Solid tumor 27.3% [23.6-31.2] 8.9% [6.6-11.5] 33% [28.8-37.3] 15.9% [12.7-19.4]
BMFS 46.8% [28.6-63.1] 28.1% [13.8-44.3] 19.4% [7.6-35.2] 6.5% [1.1-19]
P value .030699 .0040158 .06477 .64736
IF MDS or MPN MDS (n = 3258) 27.5% [25.9-29.1] 12.2% [11-13.4] 35% [33.2-36.9] 15.1% [13.8-16.5]
MPN n = (663) 28.1% [24.6-31.7] 11.2% [8.8-13.8] 32.3% [28.3-36.4] 15.7% [12.7-19]
P value .76966 .48512 .17495 .67761
If solid tumor Other solid tumor (n = 213) 22.6% [17.2-28.5] 8.2% [5-12.4] 34.4% [27.6-41.4] 13.8% [9.2-19.3]
Breast cancer (n = 324) 30.5% [25.4-35.6] 9.3% [6.4-12.9] 32.1% [26.7-37.5] 17.2% [13.1-21.9]
P value .034002 .66059 .6327 .22558
Status at transplant CR1 26.1% [24.4-27.8] 9.5% [8.4-10.7] 37% [35-39.1] 15.8% [14.2-17.4]
CR2/3 29% [23.7-34.5] 11.8% [8.3-15.9] 33.3% [27.3-39.4] 17.8% [13.2-23.1]
Active disease 30.4% [28.4-32.5] 14.9% [13.4-16.5] 29% [26.8-31.1] 13.6% [12-15.3]
P value .0048968 1.5171e-07 4.0372e-07 .027861
Donor type MSD 25.5% [23.3-27.8] 11.2% [9.6-12.9] 34.8% [32.2-37.4] 17.1% [15.1-19.3]
UD 10/10 28.2% [25.8-30.7] 11.3% [9.7-13.2] 35% [32.2-37.8] 15.3% [13.2-17.5]
UD 9/10 34.1% [29.3-39] 15% [11.6-18.9] 33.6% [28.5-38.8] 16.2% [12.4-20.5]
Haploidentical 24.7% [19.9-29.7] 9.5% [6.5-13.2] 24.3% [19.2-29.8] 9.1% [5.9-13]
CBT 33.3% [26.2-40.6] 16.1% [10.9-22.1] 24% [17.6-31] 10.3% [6.2-15.7]
P value .0050115 .14505 .00022358 .0002393
Values are HRs with 95% CIs in brackets.
Table 8
Multivariable Analysis of aGVHD and cGVHD
GRFS aGVHD Grades II-IV cGVHD
HR CI P HR CI P HR CI P
CR1 (reference 1 1 1
CR2/3 1.218 1.03-1.44 .02148 1.185 .907-1.548 .21445 1.146 .892-1.473 .28526
Active disease 1.546 1.425-1.676 <.001 1.309 1.149-1.491 .001 1.197 1.054-1.36 .00565
MDS (reference) 1 1 1
MPN 1.21 1.069-1.369 .00258 1.089 .887-1.338 .41601 .928 .753-1.145 .48645
Lymphoma 1.273 1.062-1.526 .00891 1.365 1.032-1.804 .02916 .861 .634-1.17 .33986
OMHD 1.002 .768-1.306 .98944 .802 .512-1.258 .33677 .775 .505-1.189 .24358
Solid tumor 1.006 .878-1.154 .92844 1.048 .839-1.309 .67761 1.059 .862-1.301 .58461
BMFS .5 .258-.969 .04007 1.733 .853-3.522 .12862 .436 .162-1.174 .10046
Age (per 10 yr) 1.058 1.02-1.098 .00261 .971 .917-1.028 .31767 1.014 .958-1.073 .63252
Good risk cytogenetics 1 1 1
Intermediate risk 1.122 .801-1.572 .50255 .953 .578-1.572 .85122 1.485 .935-2.357 .09354
Adverse risk 1.682 1.196-2.367 .00283 1.062 .637-1.77 .81817 1.266 .783-2.048 .33535
NA/failed 1.328 .946-1.864 .10063 .968 .585-1.602 .89846 1.542 .966-2.459 .06923
KPS > 80% .702 .618-.798 <.001 1.121 .889-1.412 .3348 1.084 .842-1.396 .53188
MSD 1 1 1
UD 10/10 .918 .824-1.024 .12405 1.465 1.226-1.751 3e-05 1.084 .921-1.275 .33372
UD 9/10 1.111 .958-1.288 .1626 1.885 1.496-2.377 <10-5 1.188 .941-1.499 .14712
Haploidentical 1.037 .88-1.221 .66706 1.022 .768-1.361 .88051 .755 .568-1.005 .05406
CBT 1.044 .825-1.322 .71901 1.494 1.033-2.162 .03289 .434 .272-.69 .00043
Patient female vs. male .925 .854-1.002 .05503 .864 .759-.983 .02672 .914 .806-1.036 .15804
Donor female vs. male 1.118 1.032-1.211 .00637 1.129 .992-1.285 .06676 1.269 1.122-1.435 .00014
MAC vs. RIC 1.05 .966-1.142 .25239 1.234 1.08-1.41 .00194 1 .876-1.141 .99958
Patient CMV positive 1.097 1.007-1.194 .03375 1.054 .918-1.209 .45777 1.001 .879-1.14 .99069
Donor CMV positive .974 .898-1.056 .5222 .928 .814-1.058 .26465 1.055 .93-1.197 .40696
In vivo TCD .885 .81-.968 .00718 .712 .618-.821 <.001 .634 .553-.726 <.001
Ex vivo TCD 1.235 .993-1.536 .05795 1.014 .687-1.498 .94245 .789 .515-1.208 .27592
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oversimplifying the true biology of these diseases. Some data
suggest that non-MDS–related sAML may have worse out-
comes [12], and perhaps differentiating between these may
be important in future studies because these may be more
biologically distinct that previously believed. It is possible that
patients in this cohort who had chronic myelomonocytic leu-
kemia or other MPNsmay have had poorer outcomes, but this
was not able to be delineated within this study. However, con-
sistent with the literature is that age, adverse cytogenetics,
and poor disease control affect transplant outcomes, and it
is possible these are more important variables than already
known pretransplant patient variables. This may be helpful
in patient counseling and guidance as to the expected out-
comes post-transplant. Additionally, as data regarding
molecular mutations such as TP53, TET2, ASXL1, RUX1, NRAS,
and IDH2 and their impact on AML outcomes, including in
the post-transplant setting, continue to emerge, these also
will need to be taken into consideration in future studies and
risk stratiﬁcation for patients undergoing HCT [31-33].
Small retrospective studies have shown comparable out-
comes after allogeneic HCT for both patients with de novo
and sAML in CR1 [34]. Although this study showed good
2-year OS for all patients in this cohort, future comparison
studies with patients with de novo AML would be helpful to
further prognosticate expected outcomes between these 2
groups of AML. Additionally, as more and more patients in
need of transplant are undergoing haploidentical transplan-
tation, particularly for those in need of urgent transplant
without a matched sibling donor, this needs to be studied
further for patients with this disease [35].
Finally, future data points and data analysis of patients with
non–de novo AML may need to be distinguishable between
the speciﬁc hematologic diseases associated with the diag-
nosis of AML. The World Health Organization criteria have
evolved over the years, and the most recent 2016 version
clearly distinguishes AML with MDS-related changes and
therapy-related myeloid neoplasms as distinct subtypes [36].
Data collection of patients’ disease characteristics both pre-
and post-transplant is critical to reﬂect evolving disease cat-
egorization and subtypes as our understanding of the
heterogeneity of these diseases evolves.
In summary, our study showed that patients with sAML
had good 2-year OS, with nearly 45% OS after allogeneic
HCT. However, patients who underwent RIC had higher in-
cidence of relapses compared with those undergoing MAC.
Additional patient variables that impacted outcomes in-
cluded gender, active disease before transplant, adverse risk
cytogenetics, older age, poor KPS, and CMV positivity. As
such, all these variables need to be taken into consideration
in patients with sAML who are in need of allogeneic HCT.
Further prospective study is needed to determine if MAC is
preferred in this disease for eligible patients. Further studies
on the role of haploidentical transplant are also needed
because this type of transplant is increasingly being used
as a transplant option for patients in need of HCT. Finally,
optimization of disease control pretransplant and post-
transplant pre-emptive therapy to reduce risk of relapse
may further improve outcomes in this high-risk patient
population.
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